Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Hanmi Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA grants fast track status to Hanmi\u2019s investigational fatty liver med","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Hanmi Pharmaceutical"},{"company":"Hanmi Pharmaceutical","sponsor":"Merck & Co. Inc.","pharmaFlowCategory":"D","amount":"$870.0 million","upfrontCash":"$10.0 million","newsHeadline":"Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Hanmi Pharmaceutical"}]

Hanmi Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide

Details:

Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercialize efinopegdutidein the United States and globally.

Lead Product(s): Efinopegdutide

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM12525A

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: $870.0 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement August 04, 2020

ASK
US

Upload
your Pipeline Activity

Hanmi Pharmaceutical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

FDA grants fast track status to Hanmi’s investigational fatty liver med

Details:

The novel drug is under development with the company’s Lapscovery, a platform technology that prolongs the duration of action of biologics, making it possible for patients to take weekly or monthly administration.

Lead Product(s): HM15211

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: HM15211

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 22, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY